MedTrace Logo

A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses

NCT00935662 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2010-09-13

No results posted yet for this study

Summary

The primary objective for this study is to assess the safety and tolerability of AZD8329 when given as a single dose in increasing dose strength, and also to identify the highest tolerated dose for future studies.

Conditions

  • Healthy Men

Interventions

DRUG

AZD8329

Oral solution, single ascending doses

DRUG

Placebo

Oral solution, placebo

Sponsors & Collaborators

Principal Investigators

  • Wolfgang Kühn · Quintiles AB, Phase I Services, Uppsala, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00935662 on ClinicalTrials.gov